Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

被引：0
作者：
Luisa Klotz
Berit Grützke
Maria Eveslage
Michael Deppe
Catharina C. Gross
Lucienne Kirstein
Anita Posevitz-Fejfar
Tilman Schneider-Hohendorf
Nicholas Schwab
Sven G. Meuth
Heinz Wiendl
机构：
[1] University Hospital Münster,Department of neurology
[2] Westfaelische Wilhelms-University Münster,Institute of biostatistics and clinical research
来源：
BMC Neurology | / 15卷
关键词：
Multiple sclerosis; Natalizumab; Fingolimod; PML; Switching;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia
    Algahtani, Hussein
    Shirah, Bader
    Al Malik, Yaser
    Meftah, Ibraheem
    CLINICAL NEUROPHARMACOLOGY, 2020, 43 (02) : 35 - 38
  • [22] The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study
    Curti, Erica
    Tsantes, Elena
    Baldi, Eleonora
    Caniatti, Luisa Maria
    Ferraro, Diana
    Sola, Patrizia
    Granella, Franco
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 33 : 146 - 152
  • [23] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez-Menoyo, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Duquette, Pierre
    Yamout, Bassem, I
    Khoury, Samia
    van Pesch, Vincent
    Macdonell, Richard
    Jose Sa, Maria
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Asmi, Abdallah Al
    Tallantyre, Emma
    Robertson, Neil P.
    Coles, Alasdair
    Brown, J. William
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : 1163 - 1175
  • [24] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
    Baroncini, Damiano
    Ghezzi, Angelo
    Annovazzi, Pietro O.
    Colombo, Bruno
    Martinelli, Vittorio
    Minonzio, Giorgio
    Moiola, Lucia
    Rodegher, Mariaemma
    Zaffaroni, Mauro
    Comi, Giancarlo
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (10) : 1315 - 1326
  • [25] Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis:. case series
    Notas, Konstantinos
    Papadaki, Efrosini
    Orologas, Anastasios
    Moschou, Maria
    Kimiskidis, Vasilios K.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 38
  • [26] Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation
    Berger, Benjamin
    Baumgartner, Annette
    Rauer, Sebastian
    Mader, Irina
    Luetzen, Niklas
    Farenkopf, Ulrich
    Stich, Oliver
    JOURNAL OF NEUROIMMUNOLOGY, 2015, 282 : 118 - 122
  • [27] Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis
    Meuth, Sven G.
    Bittner, Stefan
    Seiler, Carola
    Goebel, Kerstin
    Wiendl, Heinz
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (02) : 198 - 203
  • [28] Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
    Jamroz-Wisniewska, Anna
    Zajdel, Radoslaw
    Slowik, Agnieszka
    Marona, Monika
    Wnuk, Marcin
    Adamczyk-Sowa, Monika
    Adamczyk, Bozena
    Lasek-Bal, Anetta
    Puz, Przemyslaw
    Steposz, Arkadiusz
    Krzystanek, Ewa
    Patalong-Ogiewa, Maja
    Pokryszko-Dragan, Anna
    Budrewicz, Slawomir
    Koziarska, Dorota
    Karbicka, Anna
    Wawrzyniak, Slawomir
    Fryze, Waldemar
    Furtak-Niczyporuk, Marzena
    Rejdak, Konrad
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (09)
  • [29] Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis
    Crespo, C.
    Izquierdo, G.
    Garcia-Ruiz, A.
    Granell, M.
    Brosa, M.
    NEUROLOGIA, 2014, 29 (04): : 210 - 217
  • [30] Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis
    Laiho, Aapo
    Laitinen, Tiina M.
    Hartikainen, Paivi
    Hartikainen, Juha E. K.
    Laitinen, Tomi P.
    Simula, Sakari
    BRAIN AND BEHAVIOR, 2018, 8 (02):
12345